Generated by AI
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics for neurodegenerative diseases. Clene Inc. develops oral nanotechnology-based drug candidates designed to support neuronal health and function, with programs centered on conditions such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. Its current portfolio includes investigational therapies and related platform technologies aimed at improving mitochondrial function, protecting neurons, and supporting remyelination. The company also operates activities in dietary supplements, leveraging its nanocrystal manufacturing capabilities to produce low-concentration supplement products. Headquartered in Salt Lake City, Utah, Clene Inc. plays a specialized role in the pharmaceutical market by advancing novel approaches for central nervous system disorders and related neurological conditions.
Website6550 South Millrock Drive
Salt Lake City, UT, 84121
United States
The latest articles about CLNN.
Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall 2026 Investor Confe
Summary of Nov 10's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of May 5's posts. Generated by AI.
Investors talking about CLNN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.